{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:35Z","timestamp":1793370815170,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinme.2026.100644","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:24:14Z","timestamp":1789662254000},"page":"100644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redefining care for IDH-mutant low-grade gliomas: Clinical implications of the INDIGO trial and updated guidelines"],"prefix":"10.1016","volume":"26","author":[{"given":"Kristin S.","family":"Bartman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-3868","authenticated-orcid":false,"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinme.2026.100644_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinme.2026.100644_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinme.2026.100644_bib3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.clinme.2026.100644_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/biomedicines10020246","article-title":"Impact of CDKN2A\/B homozygous deletion on the prognosis and biology of IDH-mutant glioma","volume":"10","author":"Huang","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinme.2026.100644_bib5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinme.2026.100644_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2004.99.290","article-title":"The measurement of cognitive functioning in low-grade glioma patients after radiotherapy","volume":"22","author":"Klein","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinme.2026.100644_bib7","first-page":"2175","article-title":"Impaired cognitive functioning in low-grade glioma patients: relationship to tumor localisation, radiotherapy and the use of anticonvulsants","volume":"148","author":"Klein","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.clinme.2026.100644_bib8","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(02)11398-5","article-title":"Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study","volume":"360","author":"Klein","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clinme.2026.100644_bib9","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.3390\/cells10092345","article-title":"D-2-hydroxyglutarate in glioma biology","volume":"10","author":"Chou","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.clinme.2026.100644_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11060-020-03662-x","article-title":"Characteristics of IDH-mutant gliomas with non-canonical IDH mutation","volume":"151","author":"Poetsch","year":"2021","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clinme.2026.100644_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinme.2026.100644_bib12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.clinme.2026.100644_bib13","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinme.2026.100644_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.clinme.2026.100644_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinme.2026.100644_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.clinme.2026.100644_bib17","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I Trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinme.2026.100644_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.2010","article-title":"A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1\/2 mutation (INDIGO): updated efficacy and safety","volume":"44","author":"Cloughesy","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182600093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182600093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:57:21Z","timestamp":1793368641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147021182600093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S147021182600093X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100644","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining care for IDH-mutant low-grade gliomas: Clinical implications of the INDIGO trial and updated guidelines","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100644"}}